祛脂三味方治疗非酒精性脂肪性肝炎的临床疗效及安全性分析

肝脏 ›› 2018, Vol. 23 ›› Issue (9): 778-781.

祛脂三味方治疗非酒精性脂肪性肝炎的临床疗效及安全性分析

柴海生, 张琴

200336 上海交通大学医学院(柴海生,硕士研究生在读) ;上海交通大学医学院附属同仁医院感染科(张琴)

收稿日期:2018-08-16 出版日期:2018-09-30 发布日期:2020-04-26
通讯作者: 张琴,Email: zhangq1030@163.com
基金资助:
上海市进一步加快中医药事业发展三年行动计划建设项目(ZY3-CCCX-3-3035);上海市公共卫生三年行动计划重点学科建设项目传染病与卫生微生物学(TR2017T03)

Therapeutic efficacy and safety of QZSWF in the treatment of non-alcoholic steatohepatitis

CHAI Hai-sheng, ZHANG Qin

Department of Hepatology and Infection, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China

Received:2018-08-16 Online:2018-09-30 Published:2020-04-26
Contact: ZHANG Qin, Email: zhangq1030@163.com

摘要/Abstract

摘要： 目的评估祛脂三味方治疗非酒精性脂肪性肝炎的临床疗效及安全性。方法非酒精性脂肪肝患者138例随机分为祛脂三味方观察组94例和对照组44例,在生活方式干预(饮食控制＋运动锻炼)基础上,分别使用祛脂三味方颗粒(虎杖,山楂,决明子)及安慰剂(祛脂三味方每味药剂量10%+90%糊精组成)治疗,观察治疗前后患者临床指标改善情况,并观察两组不良反应。结果与对照组相比,治疗组患者治疗6个月后肝功能改善,FibroScan显示肝脂肪变性程度好转(P<0.05),且未发生严重不良反应。结论祛脂三味方改善NASH肝脂肪变性短期疗效明显,可明显改善患者肝功能,改善肝脂肪变性程度,其安全性较高,不良反应少,值得临床推广。

关键词: 非酒精性脂肪性肝炎, 祛脂三味方, 肝脂肪变

Abstract: Objective To assess the clinical efficacy and safety of QZSWF in the treatment of non-alcoholic steatohepatitis (NASH).Methods A total of 138 NASH patients were randomly divided into observation group (94 patients) and control group (44 patients). Besides lifestyle interventions, patients were treated with QZSWF granule (polygonum cuspidatum, hawthorn , cassia seed) and placebo (10% QZSWF + 90% dextrin component), respectively. Clinical indicators of patients before and after treatment were observed. Adverse reactions in both groups were recorded. Results After 6 months of treatment, the liver function and hepatic steatosis of observation group significantly improved than those of control group (P<0.05). Furthermore, no severe adverse events were observed.Conclusion QZSWF has short-term benefits in improving hepatic steatosis and liver function showing high safety with little adverse reactions. It is worthy of clinical application.

Key words: Nonalcoholic steatohepatitis, QZSWF, Hepatic steatosis

柴海生, 张琴. 祛脂三味方治疗非酒精性脂肪性肝炎的临床疗效及安全性分析[J]. 肝脏, 2018, 23(9): 778-781.

CHAI Hai-sheng, ZHANG Qin. Therapeutic efficacy and safety of QZSWF in the treatment of non-alcoholic steatohepatitis[J]. Chinese Hepatolgy, 2018, 23(9): 778-781.

参考文献

[1] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2018,67:328-357.
[2] Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA, 2015, 314:265-277.
[3] 孙宁宁,叶永安.“土壅木郁”理论及其在肝病临床中的应用.世界中医药,2015,10:383-386.
[4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).临床肝胆病杂志,2018,34:947-957.
[5] 徐亮,李萍,陆伟,等.FibroScan(R)实施受控衰减参数诊断脂肪肝的价值.中华肝脏病杂志,2016,24:108-113.
[6] Zhang Q, Tan Y, Zhang N, et al. Polydatin supplementation ameliorates diet-induced development of insulin resistance and hepatic steatosis in rats. Mol Med Rep,2015,11:603-610.
[7] Li JS, Wang WJ, Sun Y, et al. Ursolic acid inhibits the development of nonalcoholic fatty liver disease by attenuating endoplasmic reticulum stress. Food Funct,2015,6:1643-1651.
[8] Cano A, Alonso C. Deciphering non-alcoholic fatty liver disease through metabolomics. Biochem Soc Trans,2014,42:1447-1452.
[9] Karim MF, Al-Mahtab M, Rahman S, et al. Non-alcoholic fatty liver disease (NAFLD)-A review. Mymensingh Med J, 2015,24:873-880.
[10] Wei J, Rau M, Geier A. Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment.Deutsches rzteblatt International,2014, 111:447-452.
[11] Younossi ZM, Loomba R, Rinella ME, et al. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology,2018,68:361-371.
[12] Orci LA, Gariani K, Oldani G, et al. Exercise-based interventions for nonalcoholic fatty liver disease: A Meta-analysis and Meta-regression. Clin Gastroenterol Hepatol,2016,14:1398-1411.
[13] Kovatcheva-Datchary P, Arora T. Nutrition, the gut microbiome and the metabolic syndrome. Best Pract Res Clin Gastroenterol,2013,27:59-72.
[14] Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol,2017,67:829-846.